Breaking News, Collaborations & Alliances

AMRI Gains Phase II Milestone from BMS

Sixth milestone resulting from 2005 CNS pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI will receive a $3 million milestone payment from Bristol-Myers Squibb resulting from a recently initiated Phase II clinical trial of an AMRI compound exclusively licensed to BMS. This is the sixth milestone payment originating from a 2005 agreement in which AMRI licensed to BMS its technology around CNS triple reuptake transporter inhibitors as potential improved treatments for depression and CNS diseases. This payment brings the total milestone and licensing fees earned by AMRI related ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters